Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ross Camidge

Showing results (81-90 of 317) with videos related to

Pageof 32
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2019
Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLCD Ross Camidge, Elizabeth E Kim, Tiziana Usari, et al.
Clinical Lung Cancer|November 6, 2023
CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS ProgressionJames M Jurica, Billie Carsten, Sudabeh Balakhani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 11, 2020
Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLCThomas E Stinchcombe, Robert C Doebele, Xiaofei Wang, et al.
British Journal of Clinical Pharmacology|February 7, 2008
The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processesD Ross Camidge, James J Oliver, Carolyn Skinner, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitorTerry L Ng, Rustain L Morgan, Tejas Patil, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2010
Biomarkers are here to stay for clinical research and standard carePaul A Bunn, Fred R Hirsch, Robert C Doebele, et al.
Clinical Lung Cancer|July 11, 2021
Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on PralsetinibDavid Chun Cheong Tsui, Brian D Kavanagh, Justin M Honce, et al.
Acta Oncologica (Stockholm, Sweden)|April 18, 2009
Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysisKyle E Rusthoven, Susan F Hammerman, Brian D Kavanagh, et al.
Journal of Medical Economics|September 1, 2021
Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancerCaitlin Smare, Kiran Dave, Ariadna Juarez-Garcia, et al.
Clinical Lung Cancer|December 29, 2016
Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor TherapyDaniel J Becker, Juan P Wisnivesky, Michael L Grossbard, et al.
Pageof 32

Showing results (81-90 of 317) with videos related to

Sort By:
Pageof 32
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2019
Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLCD Ross Camidge, Elizabeth E Kim, Tiziana Usari, et al.
Clinical Lung Cancer|November 6, 2023
CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS ProgressionJames M Jurica, Billie Carsten, Sudabeh Balakhani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 11, 2020
Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLCThomas E Stinchcombe, Robert C Doebele, Xiaofei Wang, et al.
British Journal of Clinical Pharmacology|February 7, 2008
The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processesD Ross Camidge, James J Oliver, Carolyn Skinner, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitorTerry L Ng, Rustain L Morgan, Tejas Patil, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 28, 2010
Biomarkers are here to stay for clinical research and standard carePaul A Bunn, Fred R Hirsch, Robert C Doebele, et al.
Clinical Lung Cancer|July 11, 2021
Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on PralsetinibDavid Chun Cheong Tsui, Brian D Kavanagh, Justin M Honce, et al.
Acta Oncologica (Stockholm, Sweden)|April 18, 2009
Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysisKyle E Rusthoven, Susan F Hammerman, Brian D Kavanagh, et al.
Journal of Medical Economics|September 1, 2021
Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancerCaitlin Smare, Kiran Dave, Ariadna Juarez-Garcia, et al.
Clinical Lung Cancer|December 29, 2016
Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor TherapyDaniel J Becker, Juan P Wisnivesky, Michael L Grossbard, et al.
Pageof 32